CD8A and neoplasm: In TME, a hypoxic environment leads to tumor resistance to PD-1/PD-L1, while apatinib can inhibit HIF/VEGFA to increase the sensitivity of immune checkpoint blockade agents and activate NK、CD4+ or CD8+ T cells.